213 related articles for article (PubMed ID: 27188854)
1. Pre-clinical evaluation of CYP 2D6 dependent drug-drug interactions between primaquine and SSRI/SNRI antidepressants.
Jin X; Potter B; Luong TL; Nelson J; Vuong C; Potter C; Xie L; Zhang J; Zhang P; Sousa J; Li Q; Pybus BS; Kreishman-Deitrick M; Hickman M; Smith PL; Paris R; Reichard G; Marcsisin SR
Malar J; 2016 May; 15(1):280. PubMed ID: 27188854
[TBL] [Abstract][Full Text] [Related]
2. Primaquine pharmacology in the context of CYP 2D6 pharmacogenomics: Current state of the art.
Marcsisin SR; Reichard G; Pybus BS
Pharmacol Ther; 2016 May; 161():1-10. PubMed ID: 27016470
[TBL] [Abstract][Full Text] [Related]
3. The metabolism of primaquine to its active metabolite is dependent on CYP 2D6.
Pybus BS; Marcsisin SR; Jin X; Deye G; Sousa JC; Li Q; Caridha D; Zeng Q; Reichard GA; Ockenhouse C; Bennett J; Walker LA; Ohrt C; Melendez V
Malar J; 2013 Jun; 12():212. PubMed ID: 23782898
[TBL] [Abstract][Full Text] [Related]
4. Differential CYP 2D6 metabolism alters primaquine pharmacokinetics.
Potter BM; Xie LH; Vuong C; Zhang J; Zhang P; Duan D; Luong TL; Bandara Herath HM; Dhammika Nanayakkara NP; Tekwani BL; Walker LA; Nolan CK; Sciotti RJ; Zottig VE; Smith PL; Paris RM; Read LT; Li Q; Pybus BS; Sousa JC; Reichard GA; Marcsisin SR
Antimicrob Agents Chemother; 2015 Apr; 59(4):2380-7. PubMed ID: 25645856
[TBL] [Abstract][Full Text] [Related]
5. Differential cytochrome P450 2D metabolism alters tafenoquine pharmacokinetics.
Vuong C; Xie LH; Potter BM; Zhang J; Zhang P; Duan D; Nolan CK; Sciotti RJ; Zottig VE; Nanayakkara NP; Tekwani BL; Walker LA; Smith PL; Paris RM; Read LT; Li Q; Pybus BS; Sousa JC; Reichard GA; Smith B; Marcsisin SR
Antimicrob Agents Chemother; 2015 Jul; 59(7):3864-9. PubMed ID: 25870069
[TBL] [Abstract][Full Text] [Related]
6. Tafenoquine and NPC-1161B require CYP 2D metabolism for anti-malarial activity: implications for the 8-aminoquinoline class of anti-malarial compounds.
Marcsisin SR; Sousa JC; Reichard GA; Caridha D; Zeng Q; Roncal N; McNulty R; Careagabarja J; Sciotti RJ; Bennett JW; Zottig VE; Deye G; Li Q; Read L; Hickman M; Dhammika Nanayakkara NP; Walker LA; Smith B; Melendez V; Pybus BS
Malar J; 2014 Jan; 13():2. PubMed ID: 24386891
[TBL] [Abstract][Full Text] [Related]
7. Pathway-specific inhibition of primaquine metabolism by chloroquine/quinine.
Fasinu PS; Tekwani BL; Avula B; Chaurasiya ND; Nanayakkara NP; Wang YH; Khan IA; Walker LA
Malar J; 2016 Sep; 15(1):466. PubMed ID: 27618912
[TBL] [Abstract][Full Text] [Related]
8. Determination of Cytochrome P450 Isoenzyme 2D6 (CYP2D6) Genotypes and Pharmacogenomic Impact on Primaquine Metabolism in an Active-Duty US Military Population.
Spring MD; Sousa JC; Li Q; Darko CA; Morrison MN; Marcsisin SR; Mills KT; Potter BM; Paolino KM; Twomey PS; Moon JE; Tosh DM; Cicatelli SB; Froude JW; Pybus BS; Oliver TG; McCarthy WF; Waters NC; Smith PL; Reichard GA; Bennett JW
J Infect Dis; 2019 Oct; 220(11):1761-1770. PubMed ID: 31549155
[TBL] [Abstract][Full Text] [Related]
9. The potential for clinically significant drug-drug interactions involving the CYP 2D6 system: effects with fluoxetine and paroxetine versus sertraline.
Preskorn SH; Shah R; Neff M; Golbeck AL; Choi J
J Psychiatr Pract; 2007 Jan; 13(1):5-12. PubMed ID: 17242587
[TBL] [Abstract][Full Text] [Related]
10. Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications.
Caccia S
Clin Pharmacokinet; 1998 Apr; 34(4):281-302. PubMed ID: 9571301
[TBL] [Abstract][Full Text] [Related]
11. PBPK modeling to predict the pharmacokinetics of venlafaxine and its active metabolite in different CYP2D6 genotypes and drug-drug interactions with clarithromycin and paroxetine.
Cho CK; Kang P; Jang CG; Lee SY; Lee YJ; Bae JW; Choi CI
Arch Pharm Res; 2024 May; 47(5):481-504. PubMed ID: 38664354
[TBL] [Abstract][Full Text] [Related]
12. Cytochrome P450 2D-mediated metabolism is not necessary for tafenoquine and primaquine to eradicate the erythrocytic stages of Plasmodium berghei.
Milner EE; Berman J; Caridha D; Dickson SP; Hickman M; Lee PJ; Marcsisin SR; Read LT; Roncal N; Vesely BA; Xie LH; Zhang J; Zhang P; Li Q
Malar J; 2016 Dec; 15(1):588. PubMed ID: 27923405
[TBL] [Abstract][Full Text] [Related]
13. Cytochrome P(450)-dependent toxic effects of primaquine on human erythrocytes.
Ganesan S; Tekwani BL; Sahu R; Tripathi LM; Walker LA
Toxicol Appl Pharmacol; 2009 Nov; 241(1):14-22. PubMed ID: 19616568
[TBL] [Abstract][Full Text] [Related]
14. Tamoxifen and CYP 2D6 inhibitors: caution.
Prescrire Int; 2011; 20(118):182-4. PubMed ID: 21751753
[TBL] [Abstract][Full Text] [Related]
15. New-Generation, Non-SSRI Antidepressants: Therapeutic Drug Monitoring and Pharmacological Interactions. Part 1: SNRIs, SMSs, SARIs.
Mandrioli R; Protti M; Mercolini L
Curr Med Chem; 2018; 25(7):772-792. PubMed ID: 28707591
[TBL] [Abstract][Full Text] [Related]
16. Economic consequences of selective serotonin reuptake inhibitor use with drugs also metabolized by the cytochrome P-450 system.
Ozminkowski RJ; Hylan TR; Melfi CA; Meneades LM; Crown WH; Croghan TW; Robinson RL
Clin Ther; 1998; 20(4):780-96. PubMed ID: 9737837
[TBL] [Abstract][Full Text] [Related]
17. Polymorphisms in the CYP 2D6 gene: association with plasma concentrations of fluoxetine and paroxetine.
Charlier C; Broly F; Lhermitte M; Pinto E; Ansseau M; Plomteux G
Ther Drug Monit; 2003 Dec; 25(6):738-42. PubMed ID: 14639062
[TBL] [Abstract][Full Text] [Related]
18. The burden and management of cytochrome P450 2D6 (CYP2D6)-mediated drug-drug interaction (DDI): co-medication of metoprolol and paroxetine or fluoxetine in the elderly.
Bahar MA; Hak E; Bos JHJ; Borgsteede SD; Wilffert B
Pharmacoepidemiol Drug Saf; 2017 Jul; 26(7):752-765. PubMed ID: 28345306
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects.
Teng R; Kujacic M; Hsia J
Clin Ther; 2014 Sep; 36(9):1217-25. PubMed ID: 25069798
[TBL] [Abstract][Full Text] [Related]
20. CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquine.
Pybus BS; Sousa JC; Jin X; Ferguson JA; Christian RE; Barnhart R; Vuong C; Sciotti RJ; Reichard GA; Kozar MP; Walker LA; Ohrt C; Melendez V
Malar J; 2012 Aug; 11():259. PubMed ID: 22856549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
